Liposome-Mediated Radiotherapeutics Within Avascular Tumor Spheroids: Comparative Dosimetry Study for Various Radionuclides, Liposome Systems, and a Targeting Antibody

作者: Dimitris Emfietzoglou , George Sgouros , Åse Ballangrud , Hong Song , Kostas Kostarelos

DOI:

关键词: BiophysicsDosimetrySpheroidDistribution (pharmacology)ChemistryLiposomeNuclear medicineConjugateRadiation therapyBiodistributionAbsorbed dose

摘要: Absorbed dose profiles within tumor spheroids simulating avascular micrometastases have been calculated for a variety of liposome- and antibody-radionuclide combinations to assess the anticipated therapeutic efficacy based on intratumoral distribution carrier systems spheroid model. Methods: Experiments studying targeting diffusion capability most clinically relevant liposome anti-PSMA (prostate-specific membrane antigen) antibody J591 prostate cancer cell line LNCaP (diameter, 150–200 μm) performed. The biodistribution data were then used as input obtain absorbed mass. dosimetric analysis was performed medium- high-energy β-emitting radionuclides (32P, 90Y, 188Re, 67Cu, 131I) 2 low-energy Auger or conversion electron emitters (123I, 125I) following point-kernel convolution method in continuous slowing-down approximation. Results: Relative calculations function distance from rim are presented. For all studied, SUV-DMPC-chol (small unilamellar vesicle-dimyristoyl-phosphatidylcholine-cholesterol) efficient penetrating deeper spheroids. β-emitters it delivered its maximum (Dmax) at 40- 50-μm depth, exhibiting an almost flat profile beyond that point, is evident by high value center (Dcore), Dcore/Dmax > 0.9; respective values 20 μm 0.85. resulted heterogeneous distribution; ratio fell 0.4 0.4–0.5 antibody. In general, 2- 10-fold “cross-fire”-related increase core observed. liposomes binding capacity (3β-[N-(N′,N′]-dimethylaminoethane)carbamoyl]cholesterol [DC-chol]), however, deliver up 40% higher Dmax relative β-emitters. surface characteristics appear noticeable influence profiles. use neutral (DMPC-chol) versus cationic (DC-chol) lipids depending radionuclide. Changing lipid N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate also had notable (up 6-fold increase), whereas effect fusogenic (dioleoylphosphatidylcholine) found be much smaller. Conclusion: It possible engineer particularly effective delivering uniform central region micrometastatic tumors, provided conjugates with appropriate constructed. view passive means solid suggested they may effectively complement antibody-based regime against leading cytotoxic levels throughout entire volume—thus, hindering recurrence.

参考文章(37)
R. P. Hill, M. G. Pallavicini, Hypoxia and the radiation response of tumors. Advances in Experimental Medicine and Biology. ,vol. 159, pp. 17- 35 ,(1983) , 10.1007/978-1-4684-7790-0_3
John N. Weinstein, William van Osdol, Kenji Fujimori, An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Research. ,vol. 51, pp. 4776- 4784 ,(1991)
Reingard Senekowitsch-Schmidtke, Judith Weber, Wolfgang Weber, Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Cancer Research. ,vol. 56, pp. 5428- 5434 ,(1996)
George Sgouros, Åse M. Ballangrud, Ann Dnistrian, Wei Hong Yang, Nina M. Lampen, Growth and characterization of LNCaP prostate cancer cell spheroids. Clinical Cancer Research. ,vol. 5, ,(1999)
D W Mason, A F Williams, The kinetics of antibody binding to membrane antigens in solution and at the cell surface Biochemical Journal. ,vol. 187, pp. 1- 20 ,(1980) , 10.1042/BJ1870001
Joseph A. O'Donoghue, Implications of nonuniform tumor doses for radioimmunotherapy. The Journal of Nuclear Medicine. ,vol. 40, pp. 1337- 1341 ,(1999)
L. M. Cobb, J. L. Humm, Nonuniformity of tumor dose in radioimmunotherapy. The Journal of Nuclear Medicine. ,vol. 31, pp. 75- 83 ,(1990)